Distribution of the human leukocyte antigen class II alleles in Brazilian patients with chronic hepatitis C virus infection

Hepatitis C virus (HCV) infection is a global medical problem. The current standard of treatment consists of the combination of peginterferon plus ribavirin. This regimen eradicates HCV in 55% of cases. The immune response to HCV is an important determinant of disease evolution and can be influenced by various host factors. HLA class II may play an important role in immune response against HCV. The objective of the present study was to determine the distribution of HLA class II (DRB1 and DQB1) alleles, their association with chronic HCV infection and their response to interferon therapy. One hundred and two unrelated white Brazilian patients with chronic HCV infection, 52 responders (45 males and 7 females) and 50 non-responders (43 males and 7 females) to antiviral treatment, were included in the study. Healthy Brazilian bone marrow donors of Caucasian origin from the same geographic area constituted the control group (HLA-DRB1, N = 99 and HLA-DQB1, N = 222 individuals). HLA class II genotyping was performed using a low-resolution DRB1, DQB1 sequence-specific primer amplification. There were higher frequencies of HLA-DRB1*13 (26.5 vs 14.1%) and HLA-DQB1*02 (52.9 vs 38.7%) in patients compared with controls; however, these were not significantly different after P correction (Pc = 0.39 and Pc = 0.082, respectively). There was no significant difference between the phenotypic frequencies of HLA-DRB1 (17.3 vs 14.0%) and HLA-DQB1 alleles in responder and non-responder HCV patients. The HLA-DRB1*07 allele was significantly more common in HCV patients (33.3 vs 12.1%) than in controls (Pc = 0.0039), suggesting that the HLA-DRB1*07 allele is associated with chronic HCV infection.88488

Hla Antigens And Susceptibility To Systemic Lupus Erythematosus In Brazilian Patients

Objective: The aim of this study was to investigate association between systemic lupus erythematosus (SLE) and HLA antigens in Caucasoid Brazilian population. Methods: The HLA-A, B, DR and DQ antigens typing was performed using microlymphocytotoxicity test. Fifty-six unrelated Brazilian Caucasoid patients with SLE were studied. Control population for HLA A and B antigen frequency consisted of one hundred-fifty nine unrelated healthy Brazilian Caucasoid and for HLA DR and DQ one hundred-forty one. SLE patients were divided in two groups: 1) with nephritis and 2) without renal involvement. Results: The frequency of HLA-B8 was significantly increased in SLE patients than in controls (25.4% vs 6.9%). HLA-DR2 was significantly increased in SLE patients than was in controls (41% vs 19.1%, RR = 2.95; p < 0.005). When SLE nephritis patients were compared to controls, the frequency of HLA-DR2 (44% vs 19.1%) and HLA-DR3 (32% vs 14.2%) were significantly increased. On the other hand, the frequency of HLA-DR2 was increased in the group of SLE patients without renal disease when compared with control group (37.5% vs 19.1%). Conclusion: Our data suggested that HLA-B8 and HLA-DR2 might have a role in the susceptibility to SLE and HLA-DR3 may be associated with nephritis in Caucasoid Brazilian population with SLE.38633233

Distribution of HLA-DRB1 alleles in a mixed population with insulin-dependent diabetes mellitus from the Southeast of Brazil

HLA class II genes are strongly associated with susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). The present study reports the HLA-DRB1 genotyping of 41 IDDM patients and 99 healthy subjects from the Southeast of Brazil (Campinas region). Both groups consisted of an ethnic mixture of Caucasian, African Negro and Amerindian origin. HLA-DRB1*03 and *04 alleles were found at significantly higher frequencies among IDDM patients compared to the controls (DRB1*03: 48.8% vs 18.2%, P&lt;0.005, RR = 4.27; DRB1*04: 43.9% vs 15.1%, P&lt;0.008, RR = 4.37) and were associated with a susceptibility to the disease. DRB1*03/*04 heterozygosity conferred a strong IDDM risk (RR = 5.44). In contrast, the HLA-DRB1*11 allele frequency was lower among IDDM patients (7.3% vs 26.3% in controls), but the difference was not significant. These data agree with those described for other populations and allow genetic characterization of IDDM in Brazi

Identification of a new allele, HLA-DRB1*1360, on a DRB5 haplotype in a Brazilian individual

The application of DNA-based methods for human leukocyte antigen (HLA) genotyping has revealed an ever-increasing degree of polymorphism within the HLA-DRB loci and has resulted in the discovery of new alleles. We have identified a new DRB1 allele that was subsequently named DRB1*1360 by the WHO Nomenclature Committee. This allele is unusual for a DRB1*13 allele, as it is present on a DRB5 haplotype rather than the normal DRB3 haplotype found in association with DRB1*13 alleles

Association Between Human Leukocyte Antigens And Graft-versus-host Disease Occurrence After Allogenic Hematopoietic Stem Cell Transplantation [associação Entre Antígenos Leucocitários Humanos E A Ocorrência Da Doença Do Enxerto Contra O Hospedeiro Após O Transplante Alogênico Decélulas-tronco Hematopoiéticas]

CONTEXT AND OBJECTIVE: Graft-versus-host disease (GVHD) is one of the complications following allogenic stem cell transplantation. This study investigated an association between human leukocyte antigen (HLA) and the occurrence of acute and chronic GVHD in patients who had received stem cell transplantations from HLA-identical siblings. DESIGN AND SETTING: Retrospective study at Hematology and Hemotherapy Center, Universidade Estadual de Campinas (Unicamp). METHODS: The participants were 176 patients whose first transplant was between 1997 and 2009. HLA genotyping was performed serologically and using the polymerase chain reaction with specific primer sequence. RESULTS: Acute GVHD was positively associated with HLA-A10 (P = 0.0007), HLA-A26 (P = 0.002), B55 (P = 0.001), DRB1 *15 (P = 0.0211) and DQB1 *05 (P = 0.038), while HLA-B16 (P = 0.0333) was more frequent in patients without acute GVHD. Chronic GVHD was positively associated with HLA-A9 (P = 0.01) and A23 (P = 0.0292) and negatively with HLA-A2 (P = 0.0031) and B53 (P = 0.0116). HLA-B35 (P = 0.0373), B49 (P = 0.0155) and B55 (P = 0.0024) were higher in patients with acute GVHD grade 3 or above, than in other patients. In patients with extensive chronic GVHD, HLA-A9 (P = 0.0004), A24 (P = 0.0059) and A26 (P = 0.0411) were higher than in other patients, while HLA-A2 was lower (P = 0.0097). CONCLUSION:This study suggests that HLA can influence the incidence and severity of acute and chronic GVHD. However, a study with a better design and more patients will be needed to confirm these results.1304219224Dickinson, A.M., Charron, D., Non-HLA immunogeneticsin hematopoietic stem cell transplantation (2005) Curr Opin Immunol, 17 (5), pp. 517-525Charron, D., Immunogenetics today: HLA, MHC and much more (2005) Curr Opin Immunol, 17 (5), pp. 493-497Mohyeddin Bonab, M., Alimoghaddam, K., Vatandoust, S., Are HLA antigens a risk factor for acute GVHD in thalassemic patients receiving HLA-identical stem cell transplantation? (2004) Transplant Proc, 36 (10), pp. 3190-3193Battiwalla, M., Hahn, T., Radovic, M., Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence (2006) Blood, 107 (5), pp. 1970-1973Storb, R., Prentice, R.L., Hansen, J.A., Thomas, E.D., Association between HLA-B antigens and acute graft-versus-host disease (1983) Lancet, 2 (8354), pp. 816-819Clark, R.E., Hermans, J., Madrigal, A., HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia (2001) BrJ Haematol, 114 (1), pp. 36-41Weisdorf, D., Hakke, R., Blazar, B., Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation (1991) Transplantation, 51 (6), pp. 1197-1203Bross, D.S., Tutschka, P.J., Farmer, E.R., Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow (1984) Blood, 63 (6), pp. 1265-1270Remberger, M., Persson, U., Hauzenberger, D., Ringdén, O., An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation (2002) Br J Haematol, 119 (3), pp. 751-759Ghavamzadeh, A., Alimoghaddam, K., Behrouzan, O., HLA and risk of acute graft versus host disease in allogenic bone marrow transplantation from an HLA-identical sibling (2002) Arch Irn Med, 5 (1), pp. 16-20. , http://www.ams.ac.ir/AIM/0251/aim025116.htm, Available from, Accessed in 2011 (Nov 22)Adams, K.M., Holmberg, L.A., Leisenring, W., Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation (2004) Blood, 104 (6), pp. 1894-1897Stern, M., Passweg, J., Tiercy, J.M., Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation (2006) Biol Blood Marrow Transplant, 12 (11), pp. 1169-1175Petersdorf, E.W., Malkki, M., Genetics of risk factors for graft-versus-host disease (2006) Semin Hematol, 43 (1), pp. 11-23Glucksberg, H., Storb, R., Fefer, A., Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors (1974) Transplantation, 18 (4), pp. 295-304Atkinson, K., Horowitz, M.M., Gale, R.P., Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease (1989) Bone Marrow Transplant, 4 (3), pp. 247-254. , Committee of the International Bone Marrow Transplant RegistryVisentainer, J.E., Lieber, S.R., Persoli, L.B., Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation (2003) Exp Hematol, 31 (11), pp. 1044-1050Vigorito, A.C., Azevedo, W.M., Marques, J.F., A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies (1998) Bone Marrow Transplant, 22 (12), pp. 1145-1151Lin, M.T., Storer, B., Martin, P.J., Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation (2003) N Engl J Med, 349 (23), pp. 2201-2210Laguila Visentainer, J.E., Lieber, S.R., Lopes Persoli, L.B., Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population (2005) Cytokine, 32 (3-4), pp. 171-177Hsu, K.C., Keever-Taylor, C.A., Wilton, A., Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes (2005) Blood, 105 (12), pp. 4878-4884Viel, D.O., Tsuneto, L.T., Sossai, C.R., IL2 andTNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation (2007) Scand J Immunol, 66 (6), pp. 703-710Azarpira, N., Ramzi, M., Aghdaie, M.H., Darai, M., Geramizadeh, B., Interleukin-10 gene polymorphism in bone marrow transplant recipients (2008) Exp Clin Transplant, 6 (1), pp. 74-79Schellekens, J., Rozemuller, E.H., Petersen, E.J., Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation (2008) Mol Immunol, 45 (8), pp. 2255-2261Visentainer, J.E.L., Sell, A.M., Franceschi, D.A., Lieber, S.R., Souza, C.A., Importância de polimorfismos de genes reguladores de citocinas em transplantes de células progenitoras hematopoiéticas [Importance of regulatory cytokine gene polymorphisms in hematopoietic stem cell transplantation] (2008) RBCF Rev Bras Ciênc Farm (Impr), 44 (4), pp. 739-74